title: Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
abstract: Current influenza vaccines stimulate neutralising antibody to the haemagglutinin antigen but as there is antigenic drift in HA it is difficult to prepare a vaccine in advance against an emergent strain. A potential strategy is to induce CD8(+) and CD4(+) T cells that recognize epitopes within internal proteins that are less subject to antigenic drift. Augmenting humoral responses to HA with T cell responses to more conserved antigens may result in a more broadly protective vaccine. In this study, we evaluate the quality of influenza specific T cell responses in a clinical trial using MVA-NP+M1 vaccination followed by influenza virus challenge. In vaccinated volunteers, the expression of Granzyme A, Perforin and CD57 on influenza HLA A*02 M158-66 antigen specific cells was higher than non-vaccinated volunteers before and after challenge despite a similar frequency of antigen specific cells. BCL2 expression was lower in vaccinated volunteers. These data indicate that antigen specific T cells are a useful additional measure for use in human vaccination or immunization studies.
authors: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom. timothy.powell@imm.ox.ac.uk
authors: Timothy J
authors: TJ
authors: Powell
authors: Yanchun
authors: Y
authors: Peng
authors: Tamara K
authors: TK
authors: Berthoud
authors: Marie-Eve
authors: ME
authors: Blais
authors: Patrick J
authors: PJ
authors: Lillie
authors: Adrian V S
authors: AV
authors: Hill
authors: Sarah L
authors: SL
authors: Rowland-Jones
authors: Andrew J
authors: AJ
authors: McMichael
authors: Sarah C
authors: SC
authors: Gilbert
authors: Tao
authors: T
authors: Dong
mesh_terms: D000293:Adolescent; D000328:Adult; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D018959:CD57 Antigens / Q000235:genetics / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology*; D053804:Granzymes / Q000235:genetics / Q000276:immunology; D015789:HLA-A2 Antigen / Q000235:genetics / Q000276:immunology; D006388:Hemagglutinins / Q000235:genetics / Q000276:immunology; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D007251:Influenza, Human / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D008875:Middle Aged; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology; D009975:Orthomyxoviridae / Q000187:drug effects / Q000276:immunology; D054353:Perforin / Q000235:genetics / Q000276:immunology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology
chemical_list: D000956:Antigens, Viral; D018959:CD57 Antigens; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D006388:Hemagglutinins; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; C560489:MVA vaccine; D009698:Nucleoproteins; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D014765:Viral Vaccines; D054353:Perforin; D053804:Granzymes
references: J Exp Med. 2007 Jul 9;204(7):1625-36
references: 17606632
references: J Infect Dis. 2012 Jan 1;205(1):20-7
references: 22080094
references: J Hyg (Lond). 1972 Dec;70(4):767-77
references: 4509641
references: J Clin Invest. 2008 Oct;118(10):3478-90
references: 18802496
references: Lancet. 2003 Nov 22;362(9397):1733-45
references: 14643124
references: J Immunol. 2006 May 15;176(10):6333-9
references: 16670345
references: Science. 1996 Oct 4;274(5284):94-6
references: 8810254
references: Clin Infect Dis. 2012 Jul;55(1):19-25
references: 22441650
references: Nat Med. 2012 Jan 29;18(2):274-80
references: 22286307
references: Vaccine. 2008 Apr 7;26(16):1990-8
references: 18339461
references: J Virol. 2010 Jul;84(13):6527-35
references: 20410263
references: J Immunol. 1999 Nov 15;163(10):5535-43
references: 10553081
references: J Immunol. 2008 Oct 15;181(8):5551-9
references: 18832713
references: Immunol Rev. 1997 Oct;159:105-17
references: 9416506
references: Virology. 2003 May 10;309(2):320-9
references: 12758178
references: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-70
references: 19918065
references: J Virol. 2008 Jun;82(11):5161-6
references: 18353950
references: Clin Infect Dis. 2011 Jan 1;52(1):1-7
references: 21148512
references: J Virol. 2008 Sep;82(18):9283-7
references: 18614638
references: N Engl J Med. 1983 Jul 7;309(1):13-7
references: 6602294
references: J Immunol. 2009 May 1;182(9):5560-9
references: 19380804
references: Clin Vaccine Immunol. 2008 Jul;15(7):1042-53
references: 18448618
references: J Exp Med. 1995 Jan 1;181(1):79-91
references: 7807026
references: Nat Med. 2002 Apr;8(4):379-85
references: 11927944
references: J Infect Dis. 2008 Mar 15;197(6):803-11
references: 18279048
references: Immunity. 2008 May;28(5):710-22
references: 18468462